Novel inhibitors in the treatment of metastatic melanoma

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Metastatic melanoma remains a challenging cancer to treat effectively.
• Targeted therapies are a key focus in developing novel treatment strategies.
• The RAS-RAF-MAP kinase and RAS-PI3K-AKT pathways are frequently implicated in melanoma pathogenesis.

Purpose of the Study:

• To review the role of the RAS-RAF-MAP kinase and RAS-PI3K-AKT pathways in melanoma.
• To discuss preclinical and clinical data on BRAF inhibition for melanoma treatment.
• To explore alternative therapeutic targets, including KIT, in specific melanoma subtypes.

Main Methods:

• Review of preclinical and clinical data on BRAF inhibition.
• Analysis of mutation frequencies (BRAF, KIT) in different melanoma subsets.
• Discussion of emerging therapeutic strategies targeting specific molecular pathways.

Main Results:

• Up to 80% of cutaneous melanomas harbor a BRAF mutation, making BRAF inhibition a significant therapeutic approach.
• Acral, mucosal, and sun-damaged cutaneous melanomas show lower BRAF mutation rates but higher KIT mutation frequencies.
• Melanomas without chronic sun damage are characterized by BRAF mutations and lack of KIT mutations.

Conclusions:

• BRAF inhibition is a crucial targeted therapy for a majority of melanomas.
• Distinct melanoma subtypes (acral, mucosal, sun-damaged) may respond differently to targeted therapies due to varying mutation profiles (KIT vs. BRAF).
• Clinical trials investigating KIT inhibition are underway for patient subsets with lower BRAF mutation frequencies.